ORTHOWORLD.com
August 2018  

In 2017, sales of spine products (excluding biologics) exceeded $9 billion worldwide, an increase of 2.2% vs. 2016, according to our estimates. The segment remains a story of large, differentiated companies losing market share to the players that derive the majority of their revenue from spine.  
 
Guest author Patrtick Vega of Corazon, a program developer for spine and orthopaedic service lines, sees a bright future for spine care as we rethink traditional business practices. He puts a greater emphasis on collaboration and a more intimate understanding of the products, services and goals for each stakeholder: provider, physician and OEM.


September issue



September issue



Membership benefit! Download today!
 

 
More updates:
 
The procedure occurred this month in Taiyuan, Shanxi Province. BKS implants and instrumentation address primary and revision procedures; >70,000 of the devices have been implanted worldwide, to date.
 
With XVS, surgeons can see and navigate inside a patient's body through skin and tissue, which may lead to easier, faster and safer procedures.
 
Less than a month after acquiring Bioventus' bone morphogenetic protein development program, VB announced that it intends to pick up the OP-1 line from Ember Therapeutics, as well.